Income Statement

v3.19.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Condensed Consolidated Statements Of Operations        
Revenues, net $ 65,976 $ 98,674 $ 131,250 $ 246,398
Operating expenses:        
Cost of implants and other costs 30,365 52,993 33,185 85,798
Research and development 135,138 281,103 59,006
Selling, general and administrative 1,497,037 785,834 2,891,702 1,377,256
Depreciation 3,340 1,302 5,534 4,748
Total operating expenses 1,665,880 840,129 3,211,524 1,526,808
Loss from operations (1,599,904) (741,455) (3,080,274) (1,280,410)
Other income (expenses):        
Interest expense, net (583,308) (480,132) (1,097,476) (942,923)
Grant income 127,737 351,796
Other miscellaneous income 14,517 14,517
Total other income (expenses) (441,054) (480,132) (731,163) (942,923)
Net loss before provision for income taxes (2,040,958) (1,221,587) (3,811,437) (2,223,333)
Income taxes
Net Loss (2,040,958) (1,221,587) (3,811,437) (2,223,333)
Non-controlling interest 1,427 45 1,455 45
Net loss attributable to BioCorRx Inc. $ (2,040,958) $ (1,221,587) $ (3,809,982) $ (2,223,333)
Net loss per common share, basic and diluted $ (0.67) $ (0.49) $ (1.34) $ (0.90)
Weighted average number of common shares outstanding, basic and diluted 3,047,447 2,504,932 2,838,814 2,484,073

Source